Blueprint Medicines Corporation
BPMC Real Time Price USDRecent trades of BPMC by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BPMC's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
BPMC Revenue by Segment or Geography
New patents grants
-
Patent Title: Wild type kit inhibitors Apr. 08, 2025
-
Patent Title: Dosing regimens of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis Mar. 18, 2025
-
Patent Title: Map4k1 inhibitors Jan. 21, 2025
-
Patent Title: Egfr inhibitors Dec. 24, 2024
-
Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Aug. 13, 2024
-
Patent Title: Map4k1 inhibitors Jul. 23, 2024
-
Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Jun. 04, 2024
-
Patent Title: Cdk2 inhibitors Apr. 30, 2024
-
Patent Title: Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making Apr. 23, 2024
-
Patent Title: Cdk2 inhibitors Mar. 19, 2024
-
Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Jan. 16, 2024
-
Patent Title: Compositions useful for treating disorders related to kit Nov. 28, 2023
-
Patent Title: Egfr inhibitors Aug. 08, 2023
-
Patent Title: Inhibitors of activin receptor-like kinase Apr. 25, 2023
-
Patent Title: Map4k1 inhibitors Dec. 27, 2022
-
Patent Title: Inhibitors of ret Mar. 22, 2022
-
Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Mar. 15, 2022
-
Patent Title: Prkc fusions Mar. 01, 2022
-
Patent Title: Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase Feb. 01, 2022
-
Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 13, 2021
-
Patent Title: Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to kit and pdgfr Jun. 22, 2021
-
Patent Title: Pik3c2g fusions Dec. 29, 2020
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Dec. 29, 2020
-
Patent Title: Compositions and methods for treating kit- and pdgfra-mediated diseases Nov. 10, 2020
-
Patent Title: Compositions useful for treating disorders related to kit Oct. 20, 2020
-
Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Sep. 15, 2020
-
Patent Title: Pik3ca fusions Jun. 02, 2020
-
Patent Title: Inhibitors of activin receptor-like kinase Jun. 02, 2020
-
Patent Title: Inhibitors of ret Mar. 10, 2020
-
Patent Title: Ntrk2 fusions Sep. 10, 2019
-
Patent Title: Raf1 fusions Aug. 13, 2019
-
Patent Title: Fgr fusions Aug. 06, 2019
-
Patent Title: Prkc fusions Aug. 06, 2019
-
Patent Title: Tert fusions Aug. 06, 2019
-
Patent Title: Compounds and compositions useful for treating disorders related to ntrk Aug. 06, 2019
-
Patent Title: Method for detection of a tecr:pkn1 or an anxa4:pkn1 gene fusion Apr. 02, 2019
-
Patent Title: Inhibitors of activin receptor-like kinase Mar. 19, 2019
-
Patent Title: Compounds useful for treating disorders related to ret Mar. 12, 2019
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Mar. 05, 2019
-
Patent Title: 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors Feb. 12, 2019
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Feb. 05, 2019
-
Patent Title: Inhibitors of ret Jan. 22, 2019
-
Patent Title: Compounds useful for treating disorders related to ret Jul. 31, 2018
-
Patent Title: Inhibitors of ret Jul. 24, 2018
-
Patent Title: Compounds and compositions useful for treating disorders related to ntrk Jul. 10, 2018
-
Patent Title: Compositions useful for treating disorders related to kit and pdgfr Jun. 19, 2018
-
Patent Title: Inhibitors of the fibroblast growth factor receptor Jun. 19, 2018
-
Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
-
Patent Title: Compositions useful for treating disorders related to kit Jun. 12, 2018
-
Patent Title: Compositions useful for treating disorders related to kit Apr. 17, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to BPMC
Recent picks made for BPMC stock on CNBC
ETFs with the largest estimated holdings in BPMC
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BPMC stock a Buy, Sell, or Hold?
- What is the price target for $BPMC stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BPMC stock?
- Who owns the most shares of $BPMC stock?
- What funds own $BPMC stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BPMC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.